SLC5A2 and hepatocellular carcinoma: In another study, Hendryx et al. conducted an extensive study using SEER-Medicare linked data and demonstrated that the initiation of SGLT2 inhibitors appeared to enhance overall survival in HCC patients who already had type 2 diabetes compared to those not using SGLT2 inhibitors [57].